Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.101
Peer-review started: July 6, 2014
First decision: August 28, 2014
Revised: October 26, 2014
Accepted: November 17, 2014
Article in press: November 19, 2014
Published online: January 27, 2015
Processing time: 188 Days and 13.1 Hours
Many patients with hepatocellular carcinoma (HCC) present with advanced disease, not amenable to curative therapies such as surgery, transplantation or radiofrequency ablation. Treatment options for this group of patients include transarterial chemoembolization (TACE) and radiation therapy. Especially TACE, delivering a highly concentrated dose of chemotherapy to tumor cells while minimizing systemic toxicity of chemotherapy, has given favorable results on local control and survival. Radiotherapy, as a therapeutic modality of internal radiation therapy with radioisotopes, has also achieved efficacious tumor control in advanced disease. On the contrary, the role of external beam radiotherapy for HCC has been limited in the past, due to the low tolerance of surrounding normal liver parenchyma. However, technological innovations in the field of radiotherapy treatment planning and delivery, have provided the means of delivering radical doses to the tumor, while sparing normal tissues. Advanced and highly conformal radiotherapy approaches such as stereotactic body radiotherapy and proton therapy, evaluated for efficacy and safety for HCC, report encouraging results. In this review, we present the role of radiotherapy in hepatocellular carcinoma patients not suitable for radical treatment.
Core tip: Treatment of hepatocellular carcinoma is challenging since it is usually associate with underlying liver morbidity. The role of radiotherapy has evolved. The combination settings with radioisotopes, transarterial chemoembolization, hyperthermia, stereotactic radiotherapy and charged particles, support the efficacy and safety of the radiation therapy.